Close Menu

NEW YORK (GenomeWeb) – NeoGenomics said after the close of the market on Tuesday that is has priced its previously announced underwritten public offering of 7 million shares of its common stock at a public offering price of $21.25 per share.

Gross proceeds to NeoGenomics from the offering are expected to be $148.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.